Company: OFIX
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0000950170-25-102384
Chunk: 8

Company: Orthofix Medical Inc.
Filing Date: 2025-08-05
Form: 10-Q
Item: Item 2
Chunk 8
---
 pro forma adjusted EBITDA of $20.6 million, with pro forma adjusted EBITDA margin expanding approximately 190 basis points compared to reported non-GAAP adjusted EBITDA for the second quarter 2024

•Six consecutive quarters of adjusted EBITDA margin expansion; positive free cash flow of $4.5 million for second quarter 2025

Results of Operations

The following table provides certain items in our condensed consolidated statements of operations as a percent of net sales:

     Three Months EndedJune 30,

     Six Months EndedJune 30,

     (Unaudited)
      
     2025(%)

     2024(%)

     2025(%)

     2024(%)

     Net sales

     100.0

     100.0

     100.0

     100.0

     Cost of sales

     31.3

     32.2

     34.2

     32.3

     Gross profit

     68.7

     67.8

     65.8

     67.7

     Sales, general, and administrative

     67.3

     67.5

     67.9

     68.7

     Research and development

     7.8

     9.1

     9.0

     9.7

     Acquisition-related amortization, impairment, and remeasurement

     1.5

     3.7

     5.3

     3.3

     Operating loss

     (7.9
     )

     (12.5
     )

     (16.4
     )

     (14.0
     )

     Net loss

     (6.9
     )

     (16.8
     )

     (16.9
     )

     (17.9
     )